Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification

研究成果: ジャーナルへの寄稿記事

5 引用 (Scopus)

抄録

In this study, we reclassified 400 consecutive glioma cases including pediatric cases, using the revised 2016 WHO classification with samples collected from the Kyushu University Brain Tumor Bank. The IDH1/2, H3F3A, key genetic markers in the 2016 classification, were analyzed using high-resolution melting, with DNA extracted from frozen tissues. The 1p/19q codeletions were evaluated using a microsatellite-based loss of heterozygosity analysis, with 18 markers, to detect loss of the entire chromosome arm. In the integrated diagnosis, 29 oligodendroglioma cases and 28 anaplastic oligodendroglioma cases were diagnosed as “IDH-mutant and 1p/19q-codeleted,” while 2 oligodendroglioma cases and 5 anaplastic oligodendroglioma cases were diagnosed as not otherwise specified (NOS). These “NOS” cases were either IDH-mutants or 1p/19q-codeleted, although characteristic oligodendroglial features were evident histologically. Better overall survival of patients with oligodendroglioma correlated with the molecular characteristic of “IDH-mutant and 1p/19q-codeleted,” rather than the WHO grade. Eleven “glioblastoma, IDH-wild-type” cases were classified as “1p/19q-codeleted”, however, chromosome 10 loss was also detected in 10 out of 11 cases. The 2016 WHO criteria for glioma classification leads to better diagnosis of patients. However, there are technical pitfalls and problems to be solved in the molecular analysis of routine diagnostics.

元の言語英語
ページ(範囲)1-9
ページ数9
ジャーナルBrain tumor pathology
DOI
出版物ステータス受理済み/印刷中 - 3 22 2018

Fingerprint

Oligodendroglioma
Glioma
Nucleic Acid Denaturation
Chromosomes, Human, Pair 10
Loss of Heterozygosity
Glioblastoma
Genetic Markers
Brain Neoplasms
Microsatellite Repeats
Chromosomes
Pediatrics
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology
  • Cancer Research

これを引用

@article{2ca510903e9b41b09a23102c02fc048c,
title = "Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification",
abstract = "In this study, we reclassified 400 consecutive glioma cases including pediatric cases, using the revised 2016 WHO classification with samples collected from the Kyushu University Brain Tumor Bank. The IDH1/2, H3F3A, key genetic markers in the 2016 classification, were analyzed using high-resolution melting, with DNA extracted from frozen tissues. The 1p/19q codeletions were evaluated using a microsatellite-based loss of heterozygosity analysis, with 18 markers, to detect loss of the entire chromosome arm. In the integrated diagnosis, 29 oligodendroglioma cases and 28 anaplastic oligodendroglioma cases were diagnosed as “IDH-mutant and 1p/19q-codeleted,” while 2 oligodendroglioma cases and 5 anaplastic oligodendroglioma cases were diagnosed as not otherwise specified (NOS). These “NOS” cases were either IDH-mutants or 1p/19q-codeleted, although characteristic oligodendroglial features were evident histologically. Better overall survival of patients with oligodendroglioma correlated with the molecular characteristic of “IDH-mutant and 1p/19q-codeleted,” rather than the WHO grade. Eleven “glioblastoma, IDH-wild-type” cases were classified as “1p/19q-codeleted”, however, chromosome 10 loss was also detected in 10 out of 11 cases. The 2016 WHO criteria for glioma classification leads to better diagnosis of patients. However, there are technical pitfalls and problems to be solved in the molecular analysis of routine diagnostics.",
author = "Yojiro Akagi and Koji Yoshimoto and Nobuhiro Hata and Daisuke Kuga and Ryusuke Hatae and Takeo Amemiya and yuhei sangatsuda and Satoshi Suzuki and Toru Iwaki and Masahiro Mizoguchi and Koji Iihara",
year = "2018",
month = "3",
day = "22",
doi = "10.1007/s10014-018-0313-4",
language = "English",
pages = "1--9",
journal = "Brain Tumor Pathology",
issn = "1433-7398",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification

AU - Akagi, Yojiro

AU - Yoshimoto, Koji

AU - Hata, Nobuhiro

AU - Kuga, Daisuke

AU - Hatae, Ryusuke

AU - Amemiya, Takeo

AU - sangatsuda, yuhei

AU - Suzuki, Satoshi

AU - Iwaki, Toru

AU - Mizoguchi, Masahiro

AU - Iihara, Koji

PY - 2018/3/22

Y1 - 2018/3/22

N2 - In this study, we reclassified 400 consecutive glioma cases including pediatric cases, using the revised 2016 WHO classification with samples collected from the Kyushu University Brain Tumor Bank. The IDH1/2, H3F3A, key genetic markers in the 2016 classification, were analyzed using high-resolution melting, with DNA extracted from frozen tissues. The 1p/19q codeletions were evaluated using a microsatellite-based loss of heterozygosity analysis, with 18 markers, to detect loss of the entire chromosome arm. In the integrated diagnosis, 29 oligodendroglioma cases and 28 anaplastic oligodendroglioma cases were diagnosed as “IDH-mutant and 1p/19q-codeleted,” while 2 oligodendroglioma cases and 5 anaplastic oligodendroglioma cases were diagnosed as not otherwise specified (NOS). These “NOS” cases were either IDH-mutants or 1p/19q-codeleted, although characteristic oligodendroglial features were evident histologically. Better overall survival of patients with oligodendroglioma correlated with the molecular characteristic of “IDH-mutant and 1p/19q-codeleted,” rather than the WHO grade. Eleven “glioblastoma, IDH-wild-type” cases were classified as “1p/19q-codeleted”, however, chromosome 10 loss was also detected in 10 out of 11 cases. The 2016 WHO criteria for glioma classification leads to better diagnosis of patients. However, there are technical pitfalls and problems to be solved in the molecular analysis of routine diagnostics.

AB - In this study, we reclassified 400 consecutive glioma cases including pediatric cases, using the revised 2016 WHO classification with samples collected from the Kyushu University Brain Tumor Bank. The IDH1/2, H3F3A, key genetic markers in the 2016 classification, were analyzed using high-resolution melting, with DNA extracted from frozen tissues. The 1p/19q codeletions were evaluated using a microsatellite-based loss of heterozygosity analysis, with 18 markers, to detect loss of the entire chromosome arm. In the integrated diagnosis, 29 oligodendroglioma cases and 28 anaplastic oligodendroglioma cases were diagnosed as “IDH-mutant and 1p/19q-codeleted,” while 2 oligodendroglioma cases and 5 anaplastic oligodendroglioma cases were diagnosed as not otherwise specified (NOS). These “NOS” cases were either IDH-mutants or 1p/19q-codeleted, although characteristic oligodendroglial features were evident histologically. Better overall survival of patients with oligodendroglioma correlated with the molecular characteristic of “IDH-mutant and 1p/19q-codeleted,” rather than the WHO grade. Eleven “glioblastoma, IDH-wild-type” cases were classified as “1p/19q-codeleted”, however, chromosome 10 loss was also detected in 10 out of 11 cases. The 2016 WHO criteria for glioma classification leads to better diagnosis of patients. However, there are technical pitfalls and problems to be solved in the molecular analysis of routine diagnostics.

UR - http://www.scopus.com/inward/record.url?scp=85044340085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044340085&partnerID=8YFLogxK

U2 - 10.1007/s10014-018-0313-4

DO - 10.1007/s10014-018-0313-4

M3 - Article

C2 - 29569163

AN - SCOPUS:85044340085

SP - 1

EP - 9

JO - Brain Tumor Pathology

JF - Brain Tumor Pathology

SN - 1433-7398

ER -